Hormone-Refractory Prostate Cancer Clinical Trial
Official title:
An Evaluation of Estramustine, Docetaxel and Zoledronate in Patients With Hormone-Refractory Adenocarcinoma of the Prostate
Purpose: The aim of this clinical trail is to evaluate the effectiveness of Zoledronate (Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone-refractory prostate cancer.
Hormone refractory prostate cancer refers to advanced disease in which the patient no longer responds to conventional hormonal treatment. When hormone therapy is no longer successful, chemotherapy is a treatment option. However, current single-agent treatment has shown to have limited benefit. In this clinical trail, investigators are evaluating the effectiveness of Zoledronate(Zometa) combined with Estramustine and Docetaxel (Taxotere) in the treatment of patients with hormone refractory prostate cancer. Zometa is a bisphosphonate, and may reduce or delay skeletal complications caused by bone metastases. Estramustine and Taxotere are chemotherapy drugs that have shown activity in hormone refractory prostate cancer. Eligible patients will be randomized to receive Estramustine and Docetaxel (Taxotere) in combination with Zometa or Zometa given alone. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03076203 -
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
|
Phase 1 | |
| Terminated |
NCT01450683 -
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
|
Phase 2 | |
| Terminated |
NCT01020305 -
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00201357 -
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00337077 -
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
| Completed |
NCT00675545 -
A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) Patients
|
Phase 2 | |
| Completed |
NCT01133704 -
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT03016741 -
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
|
Phase 4 | |
| Completed |
NCT00570700 -
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02288936 -
Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00636740 -
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
|
Phase 2 | |
| Completed |
NCT01631552 -
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01422850 -
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
|
Phase 1 | |
| Recruiting |
NCT05997615 -
Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03658434 -
Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
|
N/A | |
| Completed |
NCT00891345 -
Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy
|
Phase 1 | |
| Completed |
NCT00082134 -
Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel
|
Phase 2 | |
| Terminated |
NCT00048659 -
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
|
Phase 2 |